10-Q
Quarterly Report
Actuate Therapeutics, Inc.
ACTU
NASDAQ
CIK: 1652935
File #: 001-42139
Balance Sheet
30 line items · 2 periods
XBRL
| Item | Jun 30, 2026 | Dec 31, 2025 |
|---|---|---|
ASSETS | ||
Current assets: | ||
Cash and Cash Equivalents | 4,425,841 | 13,159,423 |
Other Non-Operating Current Assets | 322,100 | 483,996 |
Total current assets | 4,747,941 | 13,643,419 |
Other Non-Operating Non-Current Assets | 451,398 | 392,491 |
Total assets | 5,199,339 | 14,035,910 |
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
Current liabilities: | ||
Accounts Payable | 1,076,691 | 1,524,190 |
Other Non-Operating Current Liabilities | 2,304,621 | 3,567,404 |
Accrued Clinical Study Costs | 1,939,501 | 3,169,433 |
Other Accrued Expenses | 365,120 | 397,971 |
Other Current Liabilities | 386,741 | 588,304 |
Other Non-Operating Current Liabilities | 37,143 | 27,018 |
Total current liabilities | 3,805,196 | 5,706,916 |
Long term liabilities: | ||
License payable | 404,991 | 404,991 |
Total long-term liabilities | 404,991 | 404,991 |
Total liabilities | 4,210,187 | 6,111,907 |
Stockholders’ equity: | ||
Preferred Stock | 0 | 0 |
Total Stockholders' Equity | 24 | 23 |
Total Stockholders' Equity | 166,089,213 | 162,531,681 |
Total Stockholders' Equity | (165,100,085) | (154,607,701) |
Total stockholders’ equity | 989,152 | 7,924,003 |
Common Stock | 24 | 23 |
Additional Paid-in Capital | 166,089,213 | 162,531,681 |
Retained Earnings | (165,100,085) | (154,607,701) |
Total liabilities and stockholders’ equity | 5,199,339 | 14,035,910 |